CRISPR THERAPEUTICS AG COMMON SHARES (CRSP) Covered Calls

You can sell covered calls on CRISPR THERAPEUTICS AG COMMON SHARES to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CRSP (prices last updated Wed 4:16 PM ET):

CRISPR THERAPEUTICS AG COMMON SHARES (CRSP) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
47.06 -0.80 46.00 47.80 444K - 2.3B
Covered Calls For CRISPR THERAPEUTICS AG COMMON SHARES (CRSP)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Aug 17 47 0.60 47.20 -0.4% -48.7%
Sep 21 45 4.40 43.40 3.7% 35.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; and Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.